---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-25-000119"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:01:25.470437+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zentalis reports azenosertib triplet achieves 35% ORR and 5.8-month PFS in BRAFi-naïve mCRC at ASCO 2025

## Summary
- ORR of 35.3% (12/34 confirmed responses) in BRAF inhibitor-naïve patients; median DoR 6.0 months (95% CI 4.4-NE).
- Median PFS of 5.8 months (95% CI 3.9-9.2) in BRAF-naïve subset; prior BRAFi-treated patients had 1.8 months.
- MTD set at azenosertib 300 mg + encorafenib 75 mg + cetuximab 500 mg/m2; no DLTs at MTD, manageable safety.
- Most common TRAEs were asthenia (36%) and decreased appetite (34%); grade 3/4 asthenia occurred in 11% across all doses.
- Efficacy exceeded historical encorafenib + cetuximab doublet (BEACON: ORR 20%, PFS 4.2 months) in BRAF-naïve mCRC.

## SEC filing metadata
- accession: 0001725160-25-000119
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000119/0001725160-25-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000119/zntl-20250531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-25-000119
- JSON: https://secwatch.observer/filing/0001725160-25-000119.json
- Plain text: https://secwatch.observer/filing/0001725160-25-000119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.